PGx statin

The result is reported as the SLCO1B1 c.521 genotype (TT, TC or CC) and the ABCG2 c.421 genotype, with the derived transporter-function status. For SLCO1B1 the phenotype (normal, decreased or poor function) is assigned from allele function classes rather than an activity score.

A negative result reflects only the two tested variants and does not exclude reduced transporter function from untested alleles. The single-SNP SLCO1B1 assay detects c.521C but does not resolve which star-allele haplotype carries it, does not detect reduced-function alleles lacking c.521C, and does not identify copy-number variation. ABCG2 assessment rests solely on c.421C>A.

The recommends considering SLCO1B1 genotyping in the individual benefit-risk assessment before high-dose therapy.

SLCO1B1 and ABCG2 genotype can influence statin exposure and the risk of statin-associated adverse effects. The magnitude and clinical relevance of these effects differ between statins. Current genotype-based recommendations are maintained in the prescribing information and pharmacogenomic guidelines referenced below.

For current, actionable guidance consult the prescribing information for the relevant statin and the CPIC and DPWG statin guidelines, held with the other pharmacogenomic annotations at . Results are interpreted in the individual clinical context, and the treatment decision rests with the treating physician.

Content reviewed against the current guidelines on 28 July 2026. Pharmacogenomic classifications are periodically revised; the linked databases above hold the day-current version.

• Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, et al. The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. PMID: .
• Wolthuis DFGJ, Nijenhuis M, Soree B, de Boer-Veger NJ, Buunk AM, Guchelaar HJ, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between SLCO1B1 and statins and CYP2C9 and sulfonylureas. Eur J Hum Genet. 2025;33(4):413-420. PMID: .
• Swissmedic. Simvastatin (Simvastatin-Mepha) Fachinformation; SLCO1B1 c.521T>C genotyping statement and European c.521C allele frequency. Swissmedic authorisation 62612. Information last revised August 2024. Available from:
• Swissmedic. Rosuvastatin (Crestor) Fachinformation; SLCO1B1 c.521CC and ABCG2 c.421AA exposure and dose-restriction statement. Swissmedic authorisation 56139. Information last revised June 2026. Available from:
• US Food and Drug Administration. Rosuvastatin (CRESTOR) prescribing information; SLCO1B1 521 C/C pharmacogenomic statement. Label revised April 29, 2026. Available from: